Pulmoner emboli şüphesi olan hastalarda siklofilin A ve VAP-1’in tanısal değeri

Yıl 2018, Cilt: 10 Sayı: 3, 228 - 233, 30.09.2018

Aynur Sahin , Olgun Aşık Özgür Tatlı , Yunus Karaca , Selim Demir , Ahmet Menteşe , Süleyman Caner Karahan Süleyman Türedi

https://doi.org/10.21601/ortadogutipdergisi.441377

Öz

Amaç: Bu çalışmanın
amacı endotel hasarı sonucu trombosit aktivasyonu ve kümeleşmesinin
patofizyolojisinde rol oynadığı bilinen pulmoner emboli (PE) hastalığında;
endotel disfonksiyonu, platelet adezyonu ve arterial trombüs ile
ilişkelendirilen siklofilin A (CYPA) ve vasküler adezyon protein- 1
(VAP-1) adlı biyokimyasal belirteçlerin tanısal değerini araştırmaktır.

Gereç ve Yöntem: Prospektif olarak yapılan bu klinik çalışmada acil servise akut PE
şüphesi ile başvurarak çalışmaya alınan ve spiral bilgisayarlı tomografi
anjiografi ile PE varlığı değerlendirilen 165 hastanın serum CYPA ve VAP-1
düzeyi ölçüldü. Bilgisayarlı tomografi sonuçlarına göre, PE (+) ve PE (-)
olarak 2 gruba ayrılan bu hastaların ölçülen CYPA ve VAP-1 düzeyleri
birbirleriyle karşılaştırıldı.

Bulgular: Her
iki grup ölçümleri birbiriyle karşılaştırıldığında VAP-1 düzeyi bakımından
gruplar arası fark istatistiksel anlamlı bulunurken (p=0.0001), CYPA düzeyinin
bakımından bu fark istatistiksel olarak anlamlı değildi. (p=0.381).

 

Sonuç: Akut
PE’de serum VAP-1 düzeyinin tanısal olarak kullanılabileceği tespit edilmiştir.
Serum CYPA düzeyinin ise akut PE’de tanısal değeri bulunmamaktadır.

Anahtar Kelimeler

Pulmoner emboli, siklofilin A, VAP-1

The diagnostic value of cyclophilin A and VAP-1 in patients with suspected pulmonary embolism

Öz

Aim: To
investigate the diagnostic value of the biochemical markers cyclophilin A
(CYPA) and VAP-1, associated with endothelial dysfunction, platelet adhesion,
and arterial thrombus in pulmonary embolism (PE), in whose pathophysiology
platelet activation and aggregation resulting from endothelial damage are known
to be involved.

Material and Method:
Serum CYPA and VAP-1 levels of 165 patients presenting to the emergency
department with suspected acute PE and with presence of PE investigated at spiral
computerized tomography angiography were measured in this prospective clinical
study. These patients were assigned into two groups, PE (+) and PE (-), based
on the tomography results, and their CYPA and VAP-1 levels were then compared.

Results: Comparison
of the two groups’ measurements revealed a significant difference in terms of
VAP-1 levels (p=0.0001), but none for CYPA (p=0.381).

Conclusion:
Diagnostic value was determined for serum VAP-1 levels in acute PE, but CYPA
levels are of no such value.

Anahtar Kelimeler

Pulmonary embolism, VAP-1, cyclophilin A, VAP-1

Kaynakça

• Referans1. Konstantinides S, Torbicki A, Agnelli G, et al. ESC/PCS New Guidelines. Kardiol Pol. 2014;72(11):997-1053.
• Referans2. Bova C, Greco F, Misuraca G, et al. Diagnostic utility of echocardiography in patients with suspected pulmonary embolism. The American journal of emergency medicine. 2003;21(3):180-3.
• Referans3. Seizer P, Fuchs C, Ungern-Sternberg SN, et al. Platelet-bound cyclophilin A in patients with stable coronary artery disease and acute myocardial infarction. Platelets. 2016;27(2):155-8. doi:10.3109/09537104.2015.1051466.
• Referans4. Elvers M, Herrmann A, Seizer P, et al. Intracellular cyclophilin A is an important Ca(2+) regulator in platelets and critically involved in arterial thrombus formation. Blood. 2012;120(6):1317-26. doi:10.1182/blood-2011-12-398438.
• Referans5. Tian-Tian Z, Jun-Feng Z, Heng G. Functions of cyclophilin A in atherosclerosis. Exp Clin Cardiol. 2013;18(2):e118-24.
• Referans6. Pannecoeck R, Serruys D, Benmeridja L, et al. Vascular adhesion protein-1: Role in human pathology and application as a biomarker. Crit Rev Clin Lab Sci. 2015;52(6):284-300. doi:10.3109/10408363.2015.1050714.
• Referans7. Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med. 1998;188(1):17-27.
• Referans8. Aalto K, Maksimow M, Juonala M, et al. Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations. Arterioscler ThrombVascBiol.2012;32(2):52332.doi:10.1161/ATVBAHA.111.238030.
• Referans9. Altug Cakmak H, Aslan S, Erturk M, et al. Assessment of the Relationship Between Serum Vascular Adhesion Protein-1 (VAP-1) and Severity of Calcific Aortic Valve Stenosis. J Heart Valve Dis. 2015;24(6):699-706.
• Referans10. Chen DW, Zhao RM, Jin Y, et al. Plasma soluble vascular adhesion protein-1 concentration correlates with arterial stiffness: A cross-sectional study. Arch Gerontol Geriatr. 2015;61(1):67-71. doi:10.1016/j.archger.2015.04.007.
• Referans11. Airas L, Lindsberg PJ, Karjalainen-Lindsberg ML, et al. Vascular adhesion protein-1 in human ischaemic stroke. Neuropathol Appl Neurobiol. 2008;34(4):394-402. doi:10.1111/j.1365-2990.2007.00911.x.
• Referans12. Aalto K, Havulinna AS, Jalkanen S, Salomaa V, Salmi M. Soluble vascular adhesion protein-1 predicts incident major adverse cardiovascular events and improves reclassification in a finnish prospective cohort study. Circ Cardiovasc Genet. 2014;7(4):529-35. doi:10.1161/CIRCGENETICS.113.000543.
• Referans13. Sun P, Sole M, Unzeta M. Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia. Cerebrovasc Dis. 2014;37(3):171-80. doi:10.1159/000357660.
• Referans14. Ma Q, Manaenko A, Khatibi NH, Chen W, Zhang JH, Tang J. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab. 2011;31(3):881-93. doi:10.1038/jcbfm.2010.167.
• Referans15. Karaca Y, Tatli O, Aksut, N, et al. Diagnostic Value of Cyclophilin A in Acute Ischemic Stroke. Eurasian J Emerg Med. 2017;16(54):54-6. doi:10.5152/eajem.2017.35119.
• Referans16. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2011;208(1):53-66. doi:10.1084/jem.20101174.
• Referans17. Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15(6):649-56. doi:10.1038/nm.1958.
• Referans18. Jin ZG, Melaragno MG, Liao DF, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000;87(9):789-96. 19. Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem. 2000;275(1):189-96. 20. Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol. 2007;82(3):613-8. doi:10.1189/jlb.0506317.